Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 9/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 9/20 | 0.46 |
| ▸ | KMO | O15229 | 4/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12801501 | 0.88 | KMO (0.47) | IKBKETBK1KMOPIK3CA | |
| SCHEMBL20918409 | 0.85 | TBK1 (0.64) | IKBKETBK1 | |
| SCHEMBL12801120 | 0.82 | IKBKE (0.57) | IKBKETBK1 | |
| SCHEMBL12801672 | 0.82 | TBK1 (0.57) | IKBKETBK1 | |
| SCHEMBL12801583 | 0.80 | IKBKE (0.56) | IKBKETBK1 | |
| SCHEMBL12801135 | 0.80 | IKBKE (0.56) | IKBKETBK1 | |
| SCHEMBL12801392 | 0.80 | IKBKE (0.56) | IKBKETBK1 | |
| SCHEMBL14771771 | 0.79 | IKBKE (0.46) | IKBKETBK1 | |
| SCHEMBL12800939 | 0.79 | IKBKE (0.54) | IKBKETBK1 | |
| SCHEMBL12801086 | 0.79 | IKBKE (0.56) | IKBKETBK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | IKBKE 5/4885TBK1 4/4885KMO 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.